Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The travoprost intracameral implant (Gen 2) is an investigational, long-duration procedural pharmaceutical therapy developed by Glaukos Corporation for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It consists of a miniature, biocompatible titanium reservoir implanted into the iridocorneal angle, designed to provide continuous, around-the-clock elution of a proprietary formulation of travoprost, a prostaglandin F receptor agonist. This second-generation version is currently in Phase 3 clinical trials and is intended to build upon the first-generation iDose TR, potentially offering an even more extended duration of effect or optimized delivery to address patient non-compliance with daily topical eye drops.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on travoprost intracameral implant (gen 2).